| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2004;77:133-142
© 2004 The Society of Thoracic Surgeons
a Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas, USA
b Oxford Heart Centre, Oxford, United Kingdom
* Address reprint requests to Dr Frazier, Texas Heart Institute, PO Box 20345, Houston, TX 77225-0345, USA
e-mail: mmallia{at}heart.thi.tmc.edu
Presented at the Thirty-ninth Annual Meeting of The Society of Thoracic Surgeons, San Diego, CA, Jan 31–Feb 2, 2003.
BACKGROUND: We have been investigating continuous-flow circulatory support devices for 20 years. Unlike pulsatile assist devices, continuous-flow pumps have a simplified pumping mechanism and they do not require compliance chambers or valves. In the 1980s, clinical experience with the Hemopump proved a high-speed, intravascular, continuous-flow pump could safely augment the circulation. Subsequently, a decade of animal experiments with a larger, longer-term continuous-flow pump (the Jarvik 2000) confirmed the safety and efficacy of intraventricular placement, leading to its clinical application.
METHODS: We analyzed the physiologic and anatomic effect of using the Jarvik 2000 pump for cardiac support in 23 patients in whom the device was applied as a bridge to transplant under the protocol approved by the Food and Drug Administration Investigational Device Exemption. The device was used as a bridge to transplantation in 20 patients and as destination therapy in 3 patients.
RESULTS: In the bridge-to-transplant group, 14 patients underwent transplantation, 5 died during the circulatory support period and 1 is in an ongoing study. The support period lasted an average of 90 days. For the survivors, the follow-up period has averaged 16 months. Within the first 48 postoperative hours, the average cardiac index increased by 65% (from 1.77 ± 0.24 to 2.92 ± 0.60 L · min-1 · m-2, p = 0.00000002), the systemic vascular resistance decreased by 42% (from 1604 ± 427 to 930 ± 330 dynes/sec per cm2, p = 0.00001), and the pulmonary capillary wedge pressure (PCWP) decreased by 41.8% (from 23 ± 5.1 to 13.4 ± 6.6 mm Hg, p = 0.00009). Similar results were seen for the patients undergoing destination therapy. Cardiac index increased 89.5% (from 1.9 ± 0.1 to 3.6 ± 0.6, p = 0.046) and PCWP decreased by 52.2% (from 23 ± 10 to 11 ± 2, p = 0.22). In that group, 1 patient died unexpectedly from an accident 382 days after device implantation. The 2 survivors remain in New York Heart Association (NYHA) functional class I at 700 to 952 days after implantation.
CONCLUSIONS: The Jarvik 2000 can offer effective long-term support for patients with chronic heart failure and NYHA class IV status. However, the new physiology produced by continuous offloading of the heart throughout the cardiac cycle has introduced unique clinical problems. The understanding of the problems generated by this biotechnological interface is essential for obtaining optimal clinical outcomes.
This article has been cited by other articles:
|
|
 |
|
  S. D. Russell, J. G. Rogers, C. A. Milano, D. B. Dyke, F. D. Pagani, J. M. Aranda, C. T. Klodell Jr, A. J. Boyle, R. John, L. Chen, et al. Renal and Hepatic Function Improve in Advanced Heart Failure Patients During Continuous-Flow Support With the HeartMate II Left Ventricular Assist Device Circulation, December 8, 2009; 120(23): 2352 - 2357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Wilson, M. M. Givertz, G. C. Stewart, and G. H. Mudge Jr Ventricular assist devices the challenges of outpatient management. J. Am. Coll. Cardiol., October 27, 2009; 54(18): 1647 - 1659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Morshuis, A. El-Banayosy, L. Arusoglu, R. Koerfer, R. Hetzer, G. Wieselthaler, A. Pavie, and C. Nojiri European experience of DuraHeartTM magnetically levitated centrifugal left ventricular assist system Eur. J. Cardiothorac. Surg., June 1, 2009; 35(6): 1020 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Loffler, A. Straub, N. Bassler, K. Pernice, F. Beyersdorf, C. Bode, M. P. Siegenthaler, and K. Peter Evaluation of platelet activation in patients supported by the Jarvik 2000* high-rotational speed impeller ventricular assist device. J. Thorac. Cardiovasc. Surg., March 1, 2009; 137(3): 736 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Nicolini and T. Gherli Alternatives to transplantation in the surgical therapy for heart failure Eur. J. Cardiothorac. Surg., February 1, 2009; 35(2): 214 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. John, F. Kamdar, K. Liao, M. Colvin-Adams, L. Miller, L. Joyce, and A. Boyle Low thromboembolic risk for patients with the Heartmate II left ventricular assist device. J. Thorac. Cardiovasc. Surg., November 1, 2008; 136(5): 1318 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. John, F. Kamdar, K. Liao, M. Colvin-Adams, A. Boyle, and L. Joyce Improved Survival and Decreasing Incidence of Adverse Events With the HeartMate II Left Ventricular Assist Device as Bridge-to-Transplant Therapy Ann. Thorac. Surg., October 1, 2008; 86(4): 1227 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. D. Patel, E. S. Weiss, J. Schaffer, S. L. Ullrich, D. C. Rivard, A. S. Shah, S. D. Russell, and J. V. Conte Right Heart Dysfunction After Left Ventricular Assist Device Implantation: A Comparison of the Pulsatile HeartMate I and Axial-Flow HeartMate II Devices Ann. Thorac. Surg., September 1, 2008; 86(3): 832 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. W. Miller, F. D. Pagani, S. D. Russell, R. John, A. J. Boyle, K. D. Aaronson, J. V. Conte, Y. Naka, D. Mancini, R. M. Delgado, et al. Use of a Continuous-Flow Device in Patients Awaiting Heart Transplantation N. Engl. J. Med., August 30, 2007; 357(9): 885 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Feller, E. N. Sorensen, M. Haddad, R. N. Pierson, F. L. Johnson, J. M. Brown, and B. P. Griffith Clinical Outcomes Are Similar in Pulsatile and Nonpulsatile Left Ventricular Assist Device Recipients Ann. Thorac. Surg., March 1, 2007; 83(3): 1082 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Takeda, G. Matsumiya, H. Takano, M. Koh, K. Iwata, and Y. Sawa Unusual thrombus formation in the aorta after apicoaortic conduit for severe aortic stenosis J. Thorac. Cardiovasc. Surg., July 1, 2006; 132(1): 155 - 156. [Full Text] [PDF]
|
|
|
|
|
|
M. P. Siegenthaler, J. Martin, R. Gutwald, R. Bahr, S. Westaby, R. Schmelzeisen, and F. Beyersdorf Anterior Approach to Implant the Jarvik 2000 With Retroauricular Power Supply Ann. Thorac. Surg., August 1, 2005; 80(2): 745 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Siegenthaler, S. Westaby, O.H. Frazier, J. Martin, A. Banning, D. Robson, J. Pepper, P. Poole-Wilson, and F. Beyersdorf Advanced heart failure: feasibility study of long-term continuous axial flow pump support Eur. Heart J., May 2, 2005; 26(10): 1031 - 1038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Goldstein, M. Zucker, L. Arroyo, D. Baran, P. M. McCarthy, M. Loebe, and G. P. Noon Safety and feasibility trial of the MicroMed DeBakey ventricular assist device as a bridge to transplantation J. Am. Coll. Cardiol., March 15, 2005; 45(6): 962 - 963. [Full Text] [PDF]
|
|
|
|
|
|
S. P. Salzberg, M. L. Lachat, K. von Harbou, G. Zund, and M. I. Turina Normalization of high pulmonary vascular resistance with LVAD support in heart transplantation candidates Eur. J. Cardiothorac. Surg., February 1, 2005; 27(2): 222 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Fox and N. A. Nussmeier Does Gender Influence the Likelihood or Types of Complications Following Cardiac Surgery? Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2004; 8(4): 283 - 295. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
